52 related articles for article (PubMed ID: 16889571)
1. L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats.
Boonsanit D; Kanchanapangka S; Buranakarl C
Nephrology (Carlton); 2006 Aug; 11(4):313-20. PubMed ID: 16889571
[TBL] [Abstract][Full Text] [Related]
2. Effect of octreotide on oxidative stress in the erythrocyte and kidney tissue in adriamycin-induced experimental nephrotic syndrome model.
Cavdar S; Acar AG; Camyar A; Hür E; Sozmen EY; Sen S; Ozısık M; Akcay YD; Duman E; Gönen S; Akcicek F; Duman S
J Bras Nefrol; 2024; 46(1):18-28. PubMed ID: 37527531
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of l-carnitine on isoprenaline -induced heart and kidney dysfunctions: Modulation of inflammation and oxidative stress-related gene expression in rats.
Chisty TTE; Sarif S; Jahan I; Ismail IN; Chowdhury FI; Siddiqua S; Yasmin T; Islam MN; Khan F; Subhan N; Alam MA
Heliyon; 2024 Feb; 10(3):e25057. PubMed ID: 38322874
[TBL] [Abstract][Full Text] [Related]
4. Untargeted Molecular Discovery in Primary Metabolism: Collision Cross Section as a Molecular Descriptor in Ion Mobility-Mass Spectrometry.
Nichols CM; Dodds JN; Rose BS; Picache JA; Morris CB; Codreanu SG; May JC; Sherrod SD; McLean JA
Anal Chem; 2018 Dec; 90(24):14484-14492. PubMed ID: 30449086
[TBL] [Abstract][Full Text] [Related]
5. Large-Scale Structural Characterization of Drug and Drug-Like Compounds by High-Throughput Ion Mobility-Mass Spectrometry.
Hines KM; Ross DH; Davidson KL; Bush MF; Xu L
Anal Chem; 2017 Sep; 89(17):9023-9030. PubMed ID: 28764324
[TBL] [Abstract][Full Text] [Related]
6. Large-Scale Prediction of Collision Cross-Section Values for Metabolites in Ion Mobility-Mass Spectrometry.
Zhou Z; Shen X; Tu J; Zhu ZJ
Anal Chem; 2016 Nov; 88(22):11084-11091. PubMed ID: 27768289
[TBL] [Abstract][Full Text] [Related]
7. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Chen M; Suzuki A; Thakkar S; Yu K; Hu C; Tong W
Drug Discov Today; 2016 Apr; 21(4):648-53. PubMed ID: 26948801
[No Abstract] [Full Text] [Related]
8. Ion mobility derived collision cross sections to support metabolomics applications.
Paglia G; Williams JP; Menikarachchi L; Thompson JW; Tyldesley-Worster R; Halldórsson S; Rolfsson O; Moseley A; Grant D; Langridge J; Palsson BO; Astarita G
Anal Chem; 2014 Apr; 86(8):3985-93. PubMed ID: 24640936
[TBL] [Abstract][Full Text] [Related]
9. FDA-approved drug labeling for the study of drug-induced liver injury.
Chen M; Vijay V; Shi Q; Liu Z; Fang H; Tong W
Drug Discov Today; 2011 Aug; 16(15-16):697-703. PubMed ID: 21624500
[TBL] [Abstract][Full Text] [Related]
10. Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients.
Cibulka R; Racek J; Pikner R; Rajdl D; Trefil L; Vesela E; Studenovska M; Siroka R
Calcif Tissue Int; 2007 Aug; 81(2):99-106. PubMed ID: 17622482
[TBL] [Abstract][Full Text] [Related]
11. Carnitine as an antidote for acute valproate toxicity in children.
Russell S
Curr Opin Pediatr; 2007 Apr; 19(2):206-10. PubMed ID: 17496767
[TBL] [Abstract][Full Text] [Related]
12. Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells.
Delaney CE; Hopkins SP; Addison CL
Cancer Lett; 2007 Jul; 252(2):195-207. PubMed ID: 17275999
[TBL] [Abstract][Full Text] [Related]
13. Carbohydrate ingestion augments L-carnitine retention in humans.
Stephens FB; Evans CE; Constantin-Teodosiu D; Greenhaff PL
J Appl Physiol (1985); 2007 Mar; 102(3):1065-70. PubMed ID: 17138832
[TBL] [Abstract][Full Text] [Related]
14. Oral L-carnitine: metabolite formation and hemodialysis.
Bain MA; Faull R; Milne RW; Evans AM
Curr Drug Metab; 2006 Oct; 7(7):811-6. PubMed ID: 17073580
[TBL] [Abstract][Full Text] [Related]
15. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
Mancinelli A; D'Iddio S; Bisonni R; Graziano F; Lippe P; Calvani M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):19-26. PubMed ID: 16988826
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolite kinetics of oral L-carnitine in humans.
Bain MA; Milne RW; Evans AM
J Clin Pharmacol; 2006 Oct; 46(10):1163-70. PubMed ID: 16988205
[TBL] [Abstract][Full Text] [Related]
17. Phytoestrogen-derived multifunctional ligands for targeted therapy of breast cancer.
Zhang Y; Pan H; Yu C; Liu R; Xing B; Jia B; He J; Jia X; Feng X; Zhang Q; Dang W; Hu Z; Deng X; Guo P; Liu Z; Pan W
Asian J Pharm Sci; 2023 Jul; 18(4):100827. PubMed ID: 37588993
[TBL] [Abstract][Full Text] [Related]
18. L-carnitine treatment attenuates renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.
Zhao HY; Li HY; Jin J; Jin JZ; Zhang LY; Xuan MY; Jin XM; Jiang YJ; Zheng HL; Jin YS; Jin YJ; Choi BS; Yang CW; Piao SG; Li C
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S180-S195. PubMed ID: 32942841
[TBL] [Abstract][Full Text] [Related]
19. Exploring protective effect of
Tan L; Tu Y; Wang K; Han B; Peng H; He C
Chin Med; 2020; 15():79. PubMed ID: 32765640
[TBL] [Abstract][Full Text] [Related]
20. Effects of tristetraprolin on doxorubicin (adriamycin)-induced experimental kidney injury through inhibiting IL-13/STAT6 signal pathway.
Zhang Q; Wu G; Guo S; Liu Y; Liu Z
Am J Transl Res; 2020; 12(4):1203-1221. PubMed ID: 32355536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
